CANBRIDGE Aktie

>CANBRIDGE Performance

1 Woche: +5,6%

1 Monat: -2,6%

3 Monate: +18,8%

6 Monate: -0,9%

1 Jahr: +1,0%

laufendes Jahr: +18,8%

>CANBRIDGE Aktie

Name:

CANBRIDGE PHARMACEUTICALS

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG1821D1097 / A3DGDS

Symbol/ Ticker:

MF1 (Frankfurt)

Kürzel:

FRA:MF1, ETR:MF1, MF1:GR

Index:

Webseite:

https://www.canbridgephar..

Profil:

Canbridge Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of innovative therapies for the treatment of rare diseases and oncology. The company's primary function is to address the unmet medical nee..
>Volltext..

Marktkapitalisierung:

154.22 Mio. EUR

Unternehmenswert:

Umsatz:

EBITDA:

Nettogewinn:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

CANBRIDGE

Letzte Datenerhebung:

04.04.26

>CANBRIDGE Kennzahlen

Aktien/ Unternehmen:

Aktien: 511.25 Mio. St.

Frei handelbar: 72.66%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 67

Umsatz/Mitarb.: 0.15 Mio. EUR

Analysten:

Analystenrating: No rating

Kursziel: -

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>CANBRIDGE Peer Group

Gesundheit, Onkologie/ Krebs- Behandlung

>CANBRIDGE Chart & Kurs - Frankfurt
- Boerse Frankfurt
- >Profi Charts

>CANBRIDGE News

30.03.26 - 12:15	Results: CANbridge Pharmaceuticals Narrows Annual Loss to RMB246 Million (AAStocks)
	CANbridge Pharmaceuticals (02575.HK) announced its annual results for the year ended last December, reporting revenue of RMB51.772 million, up 72% YoY. The loss narrowed to RMB246 million, compared to a loss of RMB556 million in the same period last year; LPS was RMB0.53. No dividend was declared. (hc/a)~AASTOCKS Financial NewsW......

26.03.26 - 20:30	Results: CANbridge Pharmaceuticals Annual Loss Slightly Expands to RMB523 Million (AAStocks)
	CANbridge Pharmaceuticals - B (02162.HK) announced its results for the fiscal year 2025, reporting revenue of RMB716 million, representing a year-on-year increase of 67.3%. The loss slightly expanded from RMB515 million in the previous year to RMB523 million, with a loss per share of RMB1.91. No final dividend was declared. (de/......

23.02.26 - 09:51

XFRA: MWBMU - HANDELSUNTERBRECHUNG - TEIL 6 (XETRA)

SE0016797773 US5904794089 KYG8879R1048 GB00B0WJ3L68 US4385651033 US6067694041 US83600C3016 US5797801074 US60272J1034 KYG1821D1097 US6025663096 US5949728878 US5949728795 US5949728613 US5949728530 US60649T1079 KYG9891U1334 US74767N1072 CA57773Y2096 US14167R3084 US6067991041 MX01AM050019 BMG210A71016 AU000000GMG2 GB0033877555 US66980N2036 US00704R1095 JP3778270003 GRS524003001 CA6293521051 CA04017M2031 US74982T1034 CA23344V1085 CA6410701073 US6323471002 CA6261351077 US56624R1086 ID1000186505 CA86332K4000 GB00BNYM9W73 SE0017767031 AU0000253197 GB0006389398 IL0010826357 US60871R1005 SGXE27499115 JP3040880001 CA91016A1084 CA8919571023 US3903207039 IT0005568461 US43010T1043 KYG370481080 GB00BTWSXB68 CA7739151032 CA03967C2076 US87507T1016 AU0000453185 CA2924833023 AU0000226300 AU000000OFX5 CA68621J4019 US65447N1037 CNE100007CV2 SE0017833171 KYG8123S1066 US0389238769 BMG684371393 ID1000165004 SG1Q52922370 SE0015244884 CNE1000070L0 AU000000PAR5...

16.02.26 - 02:45	CANBRIDGE-B Leaps 5%+ After Announcing 14.7% Discounted Shr Placement to WUXI BIOs Subsidiary (AAStocks)
	CANBRIDGE-B (01228.HK) announced the placement of 84.0336 million shares (around 14.12% of the enlarged share capital) to WuXi Biologics HealthCare Venture, a subsidiary of WUXI BIO (02269.HK), at a price of HKD2.38 per share, a 14.7% discount to the closing price of HKD2.79 on February 13.The total fundraising from this placeme......

13.08.25 - 08:24	XFRA: MF1: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN CANBRIDGE PHARM.DL-,00001 MF1 KYG1821D1097 AB/FROM ONWARDS 13.08.2025 08:17 CET...

12.08.25 - 09:45	XFRA: MF1: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL CANBRIDGE PHARM.DL-,00001 MF1 KYG1821D1097 BAW/UFN...

12.08.25 - 09:42	XFRA: INSTRUMENT_SUSPENSION - KYG1821D1097 (XETRA)
	Instrument ID [11715535] (MF1 - KYG1821D1097) suspended...

17.05.25 - 03:45	WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA (PR Newswire)
	Enabled by WuXi Biologics' industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization. Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for......

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram